LIVZON PHARMA (01513) Income Statement & Earnings

27.700
-0.120-0.43%

Trading May 7 11:08 CST

24.60BMarket Cap11.06P/E (TTM)

LIVZON PHARMA (01513) Income Statement

All

YOY

Hide blank lines

(Q1)Mar 31, 2026

(FY)Dec 31, 2025

(Q9)Sep 30, 2025

(Q6)Jun 30, 2025

(Q1)Mar 31, 2025

(FY)Dec 31, 2024

(Q9)Sep 30, 2024

(Q6)Jun 30, 2024

(Q1)Mar 31, 2024

(FY)Dec 31, 2023

Turnover

-9.73%2.87B

1.76%12.02B

0.38%9.12B

-0.17%6.27B

-1.92%3.18B

-4.97%11.81B

-5.94%9.08B

-6.09%6.28B

-4.99%3.24B

-1.58%12.43B

Operating income

-9.73%2.87B

1.76%12.02B

0.38%9.12B

-0.17%6.27B

-1.92%3.18B

-4.97%11.81B

-5.94%9.08B

-6.09%6.28B

-4.99%3.24B

-1.58%12.43B

Operating expenses

12.08%-979.89M

-0.45%-4.1B

1.31%-3.06B

0.33%-2.13B

2.72%-1.11B

8.61%-4.08B

10.84%-3.1B

10.99%-2.14B

9.10%-1.15B

-0.09%-4.47B

Gross profit

-8.47%1.89B

2.46%7.92B

1.26%6.05B

-0.08%4.14B

-1.48%2.07B

-2.93%7.73B

-3.17%5.98B

-3.35%4.14B

-2.58%2.1B

-2.49%7.96B

Selling expenses

8.07%-735.46M

-10.02%-3.58B

-6.02%-2.6B

0.17%-1.74B

8.69%-800.02M

9.55%-3.25B

12.73%-2.46B

11.57%-1.74B

9.20%-876.11M

7.44%-3.6B

Administrative expenses

13.24%-133.45M

2.38%-598.46M

4.85%-449.64M

9.51%-299.48M

20.17%-153.81M

6.30%-613.06M

2.95%-472.58M

-6.43%-330.94M

-28.75%-192.68M

0.39%-654.27M

Research and development expenses

21.59%-169.43M

9.23%-937.95M

6.97%-683.26M

11.94%-432.05M

9.28%-216.08M

22.58%-1.03B

25.49%-734.49M

19.67%-490.66M

23.52%-238.17M

6.44%-1.33B

Profit from asset sales

-207.82%-265.13K

-101.19%-537.86K

14.81%-315.53K

-95.87%-149.72K

-128.09%-86.13K

26,621.05%45.2M

-85.45%-370.4K

76.71%-76.44K

--306.57K

-119.80%-170.44K

Revaluation surplus

-2,110.36%-16.61M

216.45%17.98M

144.49%2.45M

56.76%-7.95M

-46.59%826.05K

39.81%-15.44M

86.90%-5.5M

43.33%-18.39M

105.96%1.55M

65.92%-25.65M

-Changes in the fair value of other assets

-2,110.36%-16.61M

216.45%17.98M

144.49%2.45M

56.76%-7.95M

-46.59%826.05K

39.81%-15.44M

86.90%-5.5M

43.33%-18.39M

105.96%1.55M

65.92%-25.65M

Impairment and provision

103.72%482.12K

42.13%-109.23M

58.27%-25.51M

46.62%-17.27M

-32.89%-12.95M

41.58%-188.76M

51.86%-61.12M

38.68%-32.35M

15.15%-9.74M

-164.17%-323.1M

-Other impairment is provision

103.72%482.12K

42.13%-109.23M

58.27%-25.51M

46.62%-17.27M

-32.89%-12.95M

41.58%-188.76M

51.86%-61.12M

38.68%-32.35M

15.15%-9.74M

-164.17%-323.1M

Special items of operating profit

-8.09%51.23M

9.69%175.41M

21.23%144.38M

35.98%100M

25.62%55.74M

-40.01%159.92M

-29.88%119.09M

-51.94%73.54M

-45.08%44.37M

17.21%266.6M

Operating profit

-5.76%850.85M

1.66%2.73B

2.72%2.32B

8.71%1.67B

13.66%902.88M

25.42%2.69B

27.66%2.26B

10.65%1.53B

8.89%794.38M

2.97%2.14B

Financing income

-48.63%36.6M

20.01%297.58M

65.75%242.2M

41.62%175.24M

-6.26%71.26M

-32.65%247.96M

-46.27%146.13M

80.08%123.74M

110.53%76.02M

16.82%368.16M

Financing cost

35.03%-9.68M

35.44%-57.21M

35.99%-43.7M

35.34%-29.9M

34.66%-14.9M

13.20%-88.61M

8.59%-68.26M

5.02%-46.25M

-0.70%-22.8M

-4.65%-102.09M

Special items of earning before tax

-574.30%-2.26M

-119.77%-84.07M

-14.49%-14.38M

-39.36%-5.41M

92.46%-335.4K

-17.92%-38.25M

26.66%-12.56M

23.33%-3.88M

-55.83%-4.45M

-62.17%-32.44M

Earning before tax

-11.15%851.71M

1.99%2.86B

8.41%2.5B

13.66%1.83B

13.52%958.59M

17.77%2.81B

16.89%2.3B

13.00%1.61B

14.82%844.44M

2.24%2.38B

After-tax profit from continuing operations

-9.91%724.01M

4.62%2.41B

9.47%2.13B

14.51%1.55B

12.23%803.64M

21.44%2.3B

19.80%1.95B

15.38%1.35B

16.65%716.08M

-2.96%1.9B

Earning after tax

-9.91%724.01M

4.62%2.41B

9.47%2.13B

14.51%1.55B

12.23%803.64M

21.44%2.3B

19.80%1.95B

15.38%1.35B

16.65%716.08M

-2.96%1.9B

Minority profit

-11.88%147.1M

59.33%387.79M

37.70%376.15M

47.03%270.13M

54.20%166.93M

534.24%243.39M

1,099.85%273.16M

365.13%183.73M

238.80%108.26M

-221.40%-56.05M

Profit attributable to shareholders

-9.39%576.91M

-1.84%2.02B

4.86%1.75B

9.40%1.28B

4.75%636.71M

5.50%2.06B

4.44%1.67B

3.21%1.17B

4.45%607.82M

2.32%1.95B

Basic earnings per share

-8.45%0.65

1.34%2.27

8.29%1.96

12.60%1.43

9.23%0.71

6.67%2.24

5.23%1.81

4.10%1.27

4.84%0.65

2.94%2.1

Diluted earnings per share

-8.45%0.65

1.34%2.27

8.29%1.96

12.60%1.43

9.23%0.71

6.67%2.24

5.23%1.81

4.10%1.27

4.84%0.65

2.94%2.1

Currency Unit

CNY

Accounting Standards

CAS (2007)

Audit Opinions

Unqualified Opinion

Auditor

PwC China (Special General Partnership)

	(Q1)Mar 31, 2026	(FY)Dec 31, 2025	(Q9)Sep 30, 2025	(Q6)Jun 30, 2025	(Q1)Mar 31, 2025	(FY)Dec 31, 2024	(Q9)Sep 30, 2024	(Q6)Jun 30, 2024	(Q1)Mar 31, 2024	(FY)Dec 31, 2023
Turnover	-9.73%2.87B	1.76%12.02B	0.38%9.12B	-0.17%6.27B	-1.92%3.18B	-4.97%11.81B	-5.94%9.08B	-6.09%6.28B	-4.99%3.24B	-1.58%12.43B
Operating income	-9.73%2.87B	1.76%12.02B	0.38%9.12B	-0.17%6.27B	-1.92%3.18B	-4.97%11.81B	-5.94%9.08B	-6.09%6.28B	-4.99%3.24B	-1.58%12.43B
Operating expenses	12.08%-979.89M	-0.45%-4.1B	1.31%-3.06B	0.33%-2.13B	2.72%-1.11B	8.61%-4.08B	10.84%-3.1B	10.99%-2.14B	9.10%-1.15B	-0.09%-4.47B
Gross profit	-8.47%1.89B	2.46%7.92B	1.26%6.05B	-0.08%4.14B	-1.48%2.07B	-2.93%7.73B	-3.17%5.98B	-3.35%4.14B	-2.58%2.1B	-2.49%7.96B
Selling expenses	8.07%-735.46M	-10.02%-3.58B	-6.02%-2.6B	0.17%-1.74B	8.69%-800.02M	9.55%-3.25B	12.73%-2.46B	11.57%-1.74B	9.20%-876.11M	7.44%-3.6B
Administrative expenses	13.24%-133.45M	2.38%-598.46M	4.85%-449.64M	9.51%-299.48M	20.17%-153.81M	6.30%-613.06M	2.95%-472.58M	-6.43%-330.94M	-28.75%-192.68M	0.39%-654.27M
Research and development expenses	21.59%-169.43M	9.23%-937.95M	6.97%-683.26M	11.94%-432.05M	9.28%-216.08M	22.58%-1.03B	25.49%-734.49M	19.67%-490.66M	23.52%-238.17M	6.44%-1.33B
Profit from asset sales	-207.82%-265.13K	-101.19%-537.86K	14.81%-315.53K	-95.87%-149.72K	-128.09%-86.13K	26,621.05%45.2M	-85.45%-370.4K	76.71%-76.44K	--306.57K	-119.80%-170.44K
Revaluation surplus	-2,110.36%-16.61M	216.45%17.98M	144.49%2.45M	56.76%-7.95M	-46.59%826.05K	39.81%-15.44M	86.90%-5.5M	43.33%-18.39M	105.96%1.55M	65.92%-25.65M
-Changes in the fair value of other assets	-2,110.36%-16.61M	216.45%17.98M	144.49%2.45M	56.76%-7.95M	-46.59%826.05K	39.81%-15.44M	86.90%-5.5M	43.33%-18.39M	105.96%1.55M	65.92%-25.65M
Impairment and provision	103.72%482.12K	42.13%-109.23M	58.27%-25.51M	46.62%-17.27M	-32.89%-12.95M	41.58%-188.76M	51.86%-61.12M	38.68%-32.35M	15.15%-9.74M	-164.17%-323.1M
-Other impairment is provision	103.72%482.12K	42.13%-109.23M	58.27%-25.51M	46.62%-17.27M	-32.89%-12.95M	41.58%-188.76M	51.86%-61.12M	38.68%-32.35M	15.15%-9.74M	-164.17%-323.1M
Special items of operating profit	-8.09%51.23M	9.69%175.41M	21.23%144.38M	35.98%100M	25.62%55.74M	-40.01%159.92M	-29.88%119.09M	-51.94%73.54M	-45.08%44.37M	17.21%266.6M
Operating profit	-5.76%850.85M	1.66%2.73B	2.72%2.32B	8.71%1.67B	13.66%902.88M	25.42%2.69B	27.66%2.26B	10.65%1.53B	8.89%794.38M	2.97%2.14B
Financing income	-48.63%36.6M	20.01%297.58M	65.75%242.2M	41.62%175.24M	-6.26%71.26M	-32.65%247.96M	-46.27%146.13M	80.08%123.74M	110.53%76.02M	16.82%368.16M
Financing cost	35.03%-9.68M	35.44%-57.21M	35.99%-43.7M	35.34%-29.9M	34.66%-14.9M	13.20%-88.61M	8.59%-68.26M	5.02%-46.25M	-0.70%-22.8M	-4.65%-102.09M
Special items of earning before tax	-574.30%-2.26M	-119.77%-84.07M	-14.49%-14.38M	-39.36%-5.41M	92.46%-335.4K	-17.92%-38.25M	26.66%-12.56M	23.33%-3.88M	-55.83%-4.45M	-62.17%-32.44M
Earning before tax	-11.15%851.71M	1.99%2.86B	8.41%2.5B	13.66%1.83B	13.52%958.59M	17.77%2.81B	16.89%2.3B	13.00%1.61B	14.82%844.44M	2.24%2.38B
After-tax profit from continuing operations	-9.91%724.01M	4.62%2.41B	9.47%2.13B	14.51%1.55B	12.23%803.64M	21.44%2.3B	19.80%1.95B	15.38%1.35B	16.65%716.08M	-2.96%1.9B
Earning after tax	-9.91%724.01M	4.62%2.41B	9.47%2.13B	14.51%1.55B	12.23%803.64M	21.44%2.3B	19.80%1.95B	15.38%1.35B	16.65%716.08M	-2.96%1.9B
Minority profit	-11.88%147.1M	59.33%387.79M	37.70%376.15M	47.03%270.13M	54.20%166.93M	534.24%243.39M	1,099.85%273.16M	365.13%183.73M	238.80%108.26M	-221.40%-56.05M
Profit attributable to shareholders	-9.39%576.91M	-1.84%2.02B	4.86%1.75B	9.40%1.28B	4.75%636.71M	5.50%2.06B	4.44%1.67B	3.21%1.17B	4.45%607.82M	2.32%1.95B
Basic earnings per share	-8.45%0.65	1.34%2.27	8.29%1.96	12.60%1.43	9.23%0.71	6.67%2.24	5.23%1.81	4.10%1.27	4.84%0.65	2.94%2.1
Diluted earnings per share	-8.45%0.65	1.34%2.27	8.29%1.96	12.60%1.43	9.23%0.71	6.67%2.24	5.23%1.81	4.10%1.27	4.84%0.65	2.94%2.1
Currency Unit	CNY	CNY	CNY	CNY	CNY	CNY	CNY	CNY	CNY	CNY
Accounting Standards	CAS (2007)	CAS (2007)	CAS (2007)	CAS (2007)	CAS (2007)	CAS (2007)	CAS (2007)	CAS (2007)	CAS (2007)	CAS (2007)
Audit Opinions	--	Unqualified Opinion	--	--	--	Unqualified Opinion	--	--	--	Unqualified Opinion
Auditor	--	PwC China (Special General Partnership)	--	--	--	PwC China (Special General Partnership)	--	--	--	PwC China (Special General Partnership)

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

China and the United States have successively adjusted multiple tariff and non-tariff measures, beginning to implement the consensus outcome Show More

牛牛課堂

Oct 13, 2025 18:05

[Opportunity Express] The US-China rivalry escalates! The rare earth industry becomes a "game-changer." How should investors respond?

Food流油

Apr 14, 2025 15:43

"Leaving the Group - Raising Taxes - Tweeting: The 'Money Making Strategy' of the Most Wild Gemini in Contemporary Times"